Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed) | RFA HG 20 015

Frequently Asked Questions (FAQs)

What is the title of this NIH funding opportunity?

The funding opportunity is titled "Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed)."

What is the Funding Opportunity Number (FOA number)?

The Funding Opportunity Number is RFA-HG-20-015.

What is the CFDA number associated with this opportunity?

The CFDA number listed is 93.172.

Which agency is offering this grant?

This is a discretionary grant opportunity offered by the National Institutes of Health (NIH).

What grant mechanism does this opportunity use?

This opportunity uses the NIH R21 mechanism, which is generally intended for exploratory and developmental research that may be higher risk but could lead to major advances.

Are clinical trials allowed under this FOA?

No. Clinical trials are explicitly not allowed under this announcement. Proposed work should focus on technology development, foundational engineering, and preclinical or non-clinical validation rather than testing interventions in human participants.

What is the main goal of the FOA?

The core goal is to support early-stage, high-impact research aimed at dramatically improving how synthetic nucleic acids are made and used, with an emphasis on transformative (not incremental) advances.

What does NIH mean by a "substantive" advance in this FOA?

The FOA defines a substantive advance as no less than a one order of magnitude improvement. Practically, applicants are expected to propose approaches that can plausibly deliver about a 10x improvement over current methods in at least one meaningful performance dimension.

What types of improvements qualify as the targeted 10x (order-of-magnitude) gain?

Examples of meaningful dimensions include synthesis accuracy and quality, throughput and speed, length and scale of constructs, reliability and reproducibility, functional capabilities of the resulting molecules, and overall efficiency and cost.

Is the FOA looking for incremental optimizations to existing methods?

No. The stated aim is step-change progress rather than incremental tuning. A proposal should be oriented toward transformative gains that make synthetic nucleic acid synthesis and synthetic constructs more capable and more affordable.

What kinds of projects are responsive to this FOA?

Projects may be responsive if they target an order-of-magnitude improvement in synthetic nucleic acid technology. This can include developing entirely new end-to-end synthesis platforms or full systems for producing synthetic nucleic acids and constructs, or focusing on major bottlenecks that currently limit performance.

Can a project focus on improving only part of the synthesis workflow?

Yes. The FOA allows projects that address key bottlenecks in underlying components that limit performance today, as long as the work is aimed at achieving a credible order-of-magnitude improvement.

What are examples of "bottlenecks" or components that could be targeted?

Examples listed include chemistry, enzymatic methods, error-correction strategies, assembly methods for longer constructs, automation and miniaturization, and new workflows that reduce hands-on steps and failure rates.

Can applicants propose a redesign of an existing system rather than building a new platform?

Yes. Another acceptable approach is to take an existing synthesis or construct-generation system and propose a major redesign or breakthrough improvement that credibly reaches the 10x threshold rather than a modest optimization.

Does the FOA encourage unconventional or non-traditional approaches?

Yes. A major theme is encouragement of approaches that differ from mainstream methods currently in wide use. The FOA explicitly welcomes exploration of alternative synthesis paradigms, unconventional chemistries, novel enzymatic strategies, and new architectures for constructing longer sequences.

Are high-risk/high-payoff proposals appropriate for this opportunity?

Yes. The FOA indicates that high-risk/high-payoff proposals are considered appropriate. Applicants do not necessarily need to present a fully mature technology at the outset, but they should make a compelling case that the concept is innovative, technically grounded, and capable of transformative improvements if successful.

What type of validation is appropriate if clinical trials are not allowed?

Based on the announcement description provided, the work should remain focused on technology development and foundational engineering, along with preclinical or non-clinical validation, rather than studies involving human participants.

Who is eligible to apply?

Eligibility is broad. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (other than higher education institutions); for-profit organizations (other than small businesses); and small businesses.

Are minority-serving institutions specifically mentioned as eligible?

Yes. The announcement highlights eligibility for categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and other similar organizations.

Are faith-based or community-based organizations eligible?

Yes. Faith-based or community-based organizations are explicitly included among the additional eligible applicant categories mentioned.

Are U.S. territories or possessions eligible?

Yes. U.S. territories or possessions are listed among the eligible applicant categories highlighted in the opportunity description.

Are foreign (non-U.S.) organizations eligible to apply?

Yes. The description indicates that non-U.S. entities (foreign organizations) and regional organizations are included among eligible applicant categories, reflecting an intent to attract a wide range of capable performers.

Are federal agencies eligible to apply?

Yes. Eligible federal agencies are mentioned among the additional eligible applicant categories highlighted.

What is the funding activity area for this opportunity?

The opportunity is categorized under the health funding activity area.

When was this opportunity created?

The opportunity was created on 2020-03-19.

What was the original closing date listed for this opportunity?

The original closing date listed was 2022-02-04.

Does the provided information state an award ceiling or number of awards?

No. The provided source text does not specify an award ceiling or the expected number of awards.

What is the central takeaway for prospective applicants?

NIH is seeking bold, technically credible R21 projects that can deliver major, measurable (about 10x) gains in synthetic nucleic acid synthesis and synthetic constructs, with attention to practical improvements such as increased efficiency and reduced costs, and without involving clinical trials.